Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE)
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference30 articles.
1. European Organisation for Research and Treatment of Cancer Data Center. Evaluation of response: new and standard criteria;Therasse;Ann Oncol,2002
2. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000
3. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas;van Glabbeke;Eur J Cancer,2002
4. New designs for phase 2 clinical trials;Estey;Blood,2003
5. Decision making process in oncology practice: is the information available and what should it consist of?;Trédaniel;Crit Rev Oncol Hematol,2005
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Association between High Antitumor Activity of Oxaliplatin and Cyclophosphamide and Constitutional GSTM1 Homozygous Deletion in an Advanced Ovarian Cancer Patient;Chemotherapy;2013
2. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study;Gynecologic Oncology;2009-12
3. Decision making process in oncology: rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE);B CANCER;2008
4. Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy;Oncology;2007
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3